AR075506A1 - Variantes de union a anti- albumina de suero - Google Patents
Variantes de union a anti- albumina de sueroInfo
- Publication number
- AR075506A1 AR075506A1 ARP100100461A ARP100100461A AR075506A1 AR 075506 A1 AR075506 A1 AR 075506A1 AR P100100461 A ARP100100461 A AR P100100461A AR P100100461 A ARP100100461 A AR P100100461A AR 075506 A1 AR075506 A1 AR 075506A1
- Authority
- AR
- Argentina
- Prior art keywords
- dom7h
- variants
- serum
- variant
- union
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente se refiere también a ligandos y conjugados de fármacos que comprenden dichas variantes, composiciones, ácido nucleicos, vectores y huéspedes. Reivindicacion 1: Una variante de dominio variable sencillo de inmunoglobulina anti-albumina de suero (SA) de DOM7h-14 (DOM7h-14 como se muestra en la Figura 1), en la que la variante comprende al menos una mutacion en la region CDR3 de 92 a 96 (numeracion de las posiciones de acuerdo con kabat) en comparacion con DOM7h-14 y en la que la variante tiene de 1 a 8 cambios en comparacion con la secuencia de aminoácidos de DOM7h-14.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15374609P | 2009-02-19 | 2009-02-19 | |
| US16399009P | 2009-03-27 | 2009-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075506A1 true AR075506A1 (es) | 2011-04-06 |
Family
ID=42306619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100461A AR075506A1 (es) | 2009-02-19 | 2010-02-17 | Variantes de union a anti- albumina de suero |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9175071B2 (es) |
| EP (1) | EP2398825B1 (es) |
| JP (1) | JP5766616B2 (es) |
| KR (1) | KR101820968B1 (es) |
| CN (2) | CN102405232B (es) |
| AR (1) | AR075506A1 (es) |
| AU (2) | AU2010215481C1 (es) |
| BR (1) | BRPI1008705B1 (es) |
| CA (1) | CA2753130C (es) |
| CL (1) | CL2011002023A1 (es) |
| CO (1) | CO6450689A2 (es) |
| DO (1) | DOP2011000269A (es) |
| EA (1) | EA027866B1 (es) |
| ES (1) | ES2654929T3 (es) |
| IL (1) | IL214481A0 (es) |
| MA (1) | MA33052B1 (es) |
| MX (1) | MX2011008752A (es) |
| PE (1) | PE20120170A1 (es) |
| SG (1) | SG173488A1 (es) |
| TW (1) | TW201042041A (es) |
| UY (1) | UY32452A (es) |
| WO (1) | WO2010094722A2 (es) |
| ZA (1) | ZA201105658B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0922772B1 (pt) * | 2008-12-05 | 2021-09-08 | Glaxo Group Limited | Domínio variável único de imunoglobulina e polipeptídeos isolados |
| UY32450A (es) | 2009-02-19 | 2010-09-30 | Glaxo Group Ltd | Variantes de unión a anti-albúmina de suero mejoradas |
| BRPI1013588A2 (pt) * | 2009-03-27 | 2016-04-19 | Glaxo Group Ltd | composição |
| CN104147611A (zh) * | 2009-09-30 | 2014-11-19 | 葛兰素集团有限公司 | 具有延长的半衰期的药物融合体和缀合物 |
| US9040668B2 (en) * | 2010-05-20 | 2015-05-26 | Glaxo Group Limited | Anti-serum albumin binding variants |
| US9012609B2 (en) | 2010-08-13 | 2015-04-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-serum albumin binding variants |
| JP6121330B2 (ja) * | 2010-09-28 | 2017-04-26 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続時間が増した改変ポリペプチド |
| EP2646467A2 (en) | 2010-12-01 | 2013-10-09 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| US20130310281A1 (en) | 2011-02-02 | 2013-11-21 | Glaxo Group Limited | Novel antigen binding proteins |
| BR112018073683A2 (pt) | 2016-05-18 | 2019-02-26 | Modernatx, Inc. | polinucleotídeos codificadores de relaxina |
| BR112019009484A2 (pt) | 2016-12-09 | 2019-07-30 | Gliknik Inc | otimização de fabricação de gl-2045, um stradomer multimerizador |
| CA3043251A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
| CN118403180A (zh) | 2017-02-16 | 2024-07-30 | 索纳特生物疗法公司 | 白蛋白结合结构域融合蛋白 |
| JP7130678B2 (ja) * | 2017-06-05 | 2022-09-05 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗ｈｓａ抗体 |
| WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| WO2019204925A1 (en) * | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Serum albumin binding antibodies for tuneable half-life extension of biologics |
| KR102204315B1 (ko) * | 2018-11-16 | 2021-01-18 | 한국세라믹기술원 | 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도 |
| WO2024097639A1 (en) * | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19713272A1 (de) | 1997-03-29 | 1998-10-08 | Junghans Uhren Gmbh | Zeitzonen-Uhr |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CA2492092A1 (en) | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| ATE479760T1 (de) | 2004-03-24 | 2010-09-15 | Domantis Ltd | Universelles signalpeptid gas1 |
| CA2569240A1 (en) | 2004-06-01 | 2005-12-15 | Domantis Limited | Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin |
| EP2769990A3 (en) | 2004-12-02 | 2015-02-25 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY |
| JP2008521426A (ja) | 2004-12-02 | 2008-06-26 | ドマンティス リミテッド | ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド |
| US20100047171A1 (en) | 2006-01-24 | 2010-02-25 | Roland Beckmann | Fusion Proteins That Contain Natural Junctions |
| GB0621513D0 (en) | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
| AU2008259590A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CA2744588A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Ligands that bind il-13 |
-
2010
- 2010-02-17 KR KR1020117021612A patent/KR101820968B1/ko active IP Right Grant
- 2010-02-17 AR ARP100100461A patent/AR075506A1/es not_active Application Discontinuation
- 2010-02-17 ES ES10706186.3T patent/ES2654929T3/es active Active
- 2010-02-17 UY UY0001032452A patent/UY32452A/es unknown
- 2010-02-17 MA MA34105A patent/MA33052B1/fr unknown
- 2010-02-17 BR BRPI1008705-2A patent/BRPI1008705B1/pt active IP Right Grant
- 2010-02-17 CN CN201080017229.6A patent/CN102405232B/zh not_active Expired - Fee Related
- 2010-02-17 AU AU2010215481A patent/AU2010215481C1/en not_active Ceased
- 2010-02-17 PE PE2011001426A patent/PE20120170A1/es not_active Application Discontinuation
- 2010-02-17 EA EA201171067A patent/EA027866B1/ru not_active IP Right Cessation
- 2010-02-17 CN CN201510340467.5A patent/CN105061593B/zh active Active
- 2010-02-17 US US13/202,355 patent/US9175071B2/en active Active
- 2010-02-17 JP JP2011550553A patent/JP5766616B2/ja active Active
- 2010-02-17 SG SG2011055340A patent/SG173488A1/en unknown
- 2010-02-17 EP EP10706186.3A patent/EP2398825B1/en active Active
- 2010-02-17 CA CA2753130A patent/CA2753130C/en active Active
- 2010-02-17 MX MX2011008752A patent/MX2011008752A/es not_active Application Discontinuation
- 2010-02-17 WO PCT/EP2010/052007 patent/WO2010094722A2/en active Application Filing
- 2010-02-22 TW TW099105015A patent/TW201042041A/zh unknown
-
2011
- 2011-08-01 ZA ZA2011/05658A patent/ZA201105658B/en unknown
- 2011-08-04 IL IL214481A patent/IL214481A0/en unknown
- 2011-08-18 CL CL2011002023A patent/CL2011002023A1/es unknown
- 2011-08-19 DO DO2011000269A patent/DOP2011000269A/es unknown
- 2011-08-30 CO CO11111117A patent/CO6450689A2/es not_active Application Discontinuation
-
2014
- 2014-05-20 AU AU2014202764A patent/AU2014202764B2/en not_active Ceased
-
2015
- 2015-09-23 US US14/862,818 patent/US9751935B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075506A1 (es) | Variantes de union a anti- albumina de suero | |
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| MX344040B (es) | Anticuerpos mejorados de la clase inmonoglubina g4 (igg4). | |
| BR112017019300A2 (pt) | conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo | |
| IN2012DN00640A (es) | ||
| AR075505A1 (es) | Variantes de union a anti- albumina de suero mejoradas | |
| CY1119567T1 (el) | Θεραπευτικα πεπτιδια | |
| CY1115030T1 (el) | Διειδικα αντι-vegf/αντι-ang-2 αντισωματα | |
| CY1116842T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
| AR087745A1 (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
| CY1115091T1 (el) | Διειδικες πρωτεϊνες προσδεσης αντιγονων | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| BR112015004022A2 (pt) | aminoácidos modificados compreendendo um grupo azido | |
| WO2016054598A3 (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| PE20121516A1 (es) | Antidotos de anticoagulantes | |
| BR112014012275A2 (pt) | purificação de proteína com a utilização de tampão bis-tris | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| AR088920A1 (es) | Purificacion de anticuerpos anti-c-met | |
| EA201291009A1 (ru) | Улучшенные связывающие варианты против сывороточного альбумина | |
| CU23795A3 (es) | Formulaciones líquidas de anticuerpo antirrábico | |
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| BR112017018778A2 (pt) | conjugados anticorpo-fármaco à base de criptoficina com ligantes autodegradantes inovadores | |
| GB2496801A (en) | A method of treating alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |